Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
Melanoma
Solutions
Online Inquiry

Melanoma

Melanoma is a type of skin cancer. It develops from melanocytes located deep in the epidermis, between layers of basal cells. Alfa Cytology is a world leader in the research of skin cancer. With our extensive experience and advanced platform, we can provide the best solutions for melanoma.

Introduction to Melanoma

Melanoma accounts for only about 1% of skin cancers but is more likely to grow and spread than other types of skin cancer and is responsible for most skin cancer deaths. The American Cancer Society's estimate for melanoma in the United States in 2024 is that about 100,640 new melanomas will be diagnosed and about 8,290 people are expected to die from melanoma. According to genomic differences, melanoma is mainly divided into four subtypes, including BRAF mutant, RAS mutant, NF1 mutation, and Triple wild type. The identification of genomic subtypes helps to suggest drug targets and experimental design.

The research approach of combined therapy for skin melanoma. Fig.1 The synergistic effect of systemic and intratumoral combination therapy in the treatment of skin melanoma. (Kasakovski, D., et al., 2021)

Therapy Development for Melanoma

Melanoma can usually be detected early and is most likely to be cured at this time. Early-stage melanoma can usually be cured through surgery, but late-stage melanoma is relatively more difficult to treat. However, new immunotherapies and targeted therapeutic drugs have changed the treatment methods for this disease.

Targeted Therapy

Based on the continuous evolution of technology, some companies are already developing specific pipelines related to potential therapies for melanoma.

Targets Therapeutics Company Molecule Type Phase
LAG-3 Favezelimab + pembrolizumab (MK-4280a) Merck Monoclonal antibody
HER3 IgG1 Patritumab deruxtecan (MK-1022) Merck Antibody-drug conjugate
/ Autogene cevumeran Genentech mRNA Vaccine
MEK Cobimetinib Genentech Small molecule

Our Services

The difficulty of curing melanoma after its spread is very high, but with the rapid development of new drugs and therapies, checkpoint inhibitors and inhibitors of protein kinase pathways have become emerging therapies. Therefore, Alfa Cytology is working on providing one-stop solutions, including but not limited to the following.

Models of Melanoma

Models of melanoma are used to study the biology of the disease, its progression, treatment response, and the development of new therapies. Alfa Cytology is a leading biological contract research organization (CRO). We have many years of experience in building melanoma tumor models. Our company offers several popular melanoma models, including but not limited to the following. Each model has its characteristics and applications.

Syngeneic Models

  • S91 melanoma model
  • Harding-Passey melanoma model
  • B16 melanoma model

Transgenic Models

  • CDK4-mutated model
  • CDKN2A-mutated model
  • TFAP2A -mutated model

Spices Options - Xiphophorus fish, guinea pig, opossum, and mouse models

Alfa Cytology is committed to the research and study of melanoma and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for melanoma. If you are interested in our service, please contact us for more information.

Reference

  1. Kasakovski, D., et al.; (2021). Advances in targeting cutaneous melanoma. Cancers, 13(9), 2090.

For research use only.